Cat.No. : AAV00119Z
Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml
Serotype: AAV Serotype 9 Storage: -80 ℃
| Cat. No. | AAV00119Z |
| Description | AAV serotype 9 particles contain firefly luciferase under CMV promoter. |
| Reporter | Luc |
| Serotype | AAV Serotype 9 |
| Application | 1. Determination of optimal MOI (multiplicity of infection), administration methods etc. 2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue. 3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery. |
| Titer | Varies lot by lot, typically ≥1x10^12 GC/mL |
| Size | Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc. |
| Storage | Store at -80℃. Avoid multiple freeze/thaw cycles. |
| Shipping | Frozen on dry ice |
| Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots. | |
| Endotoxin | Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance. |
| Purity | AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE. |
| Sterility | The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities. |
| Empty vs. Full Capsids | Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods. |
To identify host factors that may influence other critical steps in adeno-associated virus (AAV) infection, the researchers screened an siRNA library and identified several candidate genes, including PHD finger domain protein 5A (PHF5A), a U2 snRNP-related proteins. Disruption of PHF5A expression selectively enhances transgene expression from AAV by increasing transcript levels and appears to affect steps following second-strand synthesis in a serotype- and cell-type-independent manner. Genetic disruption of U2 snRNP and associated proteins such as SF3B1 and U2AF1 also increases AAV vector expression, suggesting that the U2 snRNP spliceosome complex plays a critical role in this host-mediated restriction. Notably, adenovirus coinfection and U2 snRNP inhibition appear to target common pathways that increase AAV vector expression. Furthermore, pharmacological inhibition of U2 snRNP by the potent SF3B1 inhibitor meayamycin B significantly enhanced transduction of clinically relevant cell types by AAV vectors. Further analysis revealed that the U2 snRNP protein inhibits AAV vector transgene expression by directly recognizing intact AAV capsids. In conclusion, the researchers identified U2 snRNP and related splicing factors, known to be affected during adenovirus infection, as novel host restriction factors that effectively limit AAV transgene expression.
Finally, the researchers tested the ability of meayamycin B to promote AAV transduction in various cell types, which is relevant for gene therapy applications. When primary pancreatic islets were transduced with AAV8 CMV-GFP and treated with 2 nM meayamycin B 3 hours after infection, the number of cells expressing GFP increased in drug-treated mouse islets (Figure 1A). When primary human islets were infected with AAV2 or AAV9 CMV-Luc vectors and treated with 0, 2, 5, or 20 nM meayamycin B 7 hours after infection, the researchers observed a dose-dependent increase in luciferase expression in AAV2- and AAV9-infected cells (Figure 1B). Similarly, meayamycin B treatment increased AAV2 and AAV9 transduction of primary neonatal rat cardiomyocytes as well as porcine hepatocytes (Figures 1C and 1D). These results suggest that meayamycin B can enhance transduction of multiple cell types from different host species by AAV vectors.
Figure 1. Meayamycin B increases AAV vector transduction of clinically relevant cell types. (Schreiber C A, et al., 2015)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The quality of the AAV9-CMV-Luc product is top-notch. It performed exactly as promised, with excellent reliability and consistency.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
